How JNJ (Johnson & Johnson) Makes Money in 2025: A Deep-Dive With Income Statement

Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io

Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.

Understanding how a healthcare conglomerate like Johnson & Johnson (JNJ) makes money is essential for investors and anyone interested in the business of pharmaceuticals, medical devices, and healthcare innovation. In this post, we break down JNJ's quarterly income statement (Q3 2025) using a Sankey chart to visualize the financial flows — what comes in, where it goes, and what's left as profit.

Quick Johnson & Johnson Overview

Johnson & Johnson operates as a diversified healthcare company with three primary business segments: Innovative Medicine (pharmaceuticals), MedTech (medical devices), and (formerly) Consumer Health. Revenue comes primarily from prescription drugs and advanced medical devices sold globally to hospitals, clinics, and healthcare providers. The company’s business model leverages research-driven drug development, a broad medical device portfolio, and global distribution networks. As of 2025, JNJ’s Consumer Health segment has been divested, focusing the company on higher-growth, higher-margin healthcare markets.

Revenue Breakdown

• Total Revenue (Q3 2025): $24.0B (+6.8% YoY)
  • Innovative Medicine Revenue: $15.6B (64.9% of total, +6.7% YoY)
  • MedTech Revenue: $8.43B (35.1% of total, +6.8% YoY)
  • Consumer Health Revenue: $0.0B (segment divested)
• Growth is powered by strong pharmaceutical sales (notably immunology and oncology drugs) and robust demand for surgical and interventional MedTech products.

Gross Profit and Margins

• Gross Profit: $16.7B (69.6% gross margin)
  • Cost of Revenue: $7.3B (+4.9% YoY)
  • Johnson & Johnson maintains robust margins due to its high-value pharmaceutical portfolio, scale advantages, and efficient manufacturing.
• Most costs come from raw materials for drug/device production, manufacturing, and supply chain logistics.

Operating Income and Expenses

• Operating Income: $7.1B (+34.4% YoY, 29.6% margin)
• Operating Expenses: $9.6B (–6.2% YoY)
  • R&D: $3.67B (–25.8% YoY, 15.3% of revenue) — Focused on late-stage clinical trials, next-generation therapies, and device innovation.
  • SG&A: $5.92B (+12.2% YoY, 24.7% of revenue) — Includes global sales force, marketing, and administrative infrastructure.
  • Johnson & Johnson continues to prioritize innovation in pharmaceuticals and MedTech while maintaining efficiency in corporate functions.

Net Income

• Pre-Tax Income: $7.49B (+124.5% YoY, 31.2% margin)
• Income Tax: $2.34B (31.2% effective tax rate)
• Net Income: $5.15B (+91.2% YoY, 21.5% net margin)
• Johnson & Johnson converts a significant portion of sales into profit due to its scale, pricing power, and operational discipline.

Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.

Want to see what we'll uncover next - before everyone else does?

Find Hidden Gems First!

What Drives Johnson & Johnson's Money Machine?

• Pharmaceuticals (Innovative Medicine): 65% of revenue, driven by blockbuster drugs in immunology, oncology, and neuroscience.
• MedTech Expansion: MedTech revenue up 6.8% YoY, reflecting growth in surgical robotics and minimally invasive devices.
• R&D Investment: $3.67B in Q3 2025, supporting a deep pipeline of new drugs and device innovations.
• Future Growth Areas: Cell and gene therapies, digital surgery, and global expansion, though some remain in investment phase and are not yet profitable.

Visualizing Johnson & Johnson's Financial Flows

The Sankey chart below visualizes how each dollar flows from gross revenue, through costs and expenses, down to net income. This helps investors spot where value is created, what areas weigh on profits, and how efficiently the company operates.

• Most revenue flows into gross profit, with SG&A expenses taking the largest chunk of operating costs.
• Even after large R&D and SG&A investments, 21.5% of revenue drops to the bottom line.

Key Takeaways

• Johnson & Johnson's money comes overwhelmingly from pharmaceuticals and medical devices
• High gross and net margins illustrate the power of JNJ's research-driven, diversified healthcare model
• Heavy investment in R&D, balanced by efficiency in operating costs
• Ongoing growth is driven by blockbuster drug launches and MedTech innovation

Explore More Investment Opportunities

For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:

📌 50 Undervalued Stocks (Best) overall value plays for 2025
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)

🔍 Check out these stocks on the Value Sense platform for free!

FAQ About Johnson & Johnson's Income Statement

1. What is the main source of Johnson & Johnson's revenue in 2025?

Johnson & Johnson generates over 64.9% of its revenue from Innovative Medicine (pharmaceuticals), with the remainder from MedTech (medical devices). The Consumer Health segment has been divested.

2. How profitable is Johnson & Johnson in Q3 2025?

Johnson & Johnson reported net income of $5.15B in Q3 2025, with a net margin of approximately 21.5%, reflecting strong profitability driven by high-margin pharmaceuticals and operational scale.

3. What are the largest expense categories for Johnson & Johnson?

The biggest expenses on Johnson & Johnson's income statement are operating expenses, particularly Research & Development (R&D) at $3.67B and Sales, General & Administrative (SG&A) at $5.92B in Q3 2025. R&D investment supports drug/device innovation, while SG&A covers global sales and administrative functions.

4. Why does MedTech operate at a lower margin than pharmaceuticals?

MedTech, despite generating $8.43B in revenue, operates at a lower margin due to higher manufacturing costs, regulatory compliance, and ongoing investment in new device platforms. Johnson & Johnson invests heavily in MedTech innovation, believing these will drive long-term growth—even if margins are lower than in pharmaceuticals.

5. How does Johnson & Johnson's effective tax rate compare to previous years?

Johnson & Johnson's effective tax rate in Q3 2025 was 31.2%, higher than previous years. This higher rate is primarily due to lower tax benefits from share-based compensation and changes in international tax structuring.